TOPIC:

Phase III trials show 99% SVR in types 1,2,4,5,6 after 12 week treatment, and 95% for type 3 after 8 week treatment. These trials used no NS5B inhibitor. Imagine it in combo with Sofosbuvir.

finance.yahoo.com/news/abbvie-abbv-prese...-data-152503586.html

Why they keep doing 8 week trials, especially for type 3 patients, baffles me. These drugs' exorbitant prices do not come from their manufacturing cost ... therefore, drop the price by 1/3 and sell 50% more product, get the same revenue and stop screwing around with people's lives.

AbbVie on ENDURANCE-3:
news.abbvie.com/news/eight-weeks-treatme...onic-hepatitis-c.htm

AbbVie on EXPEDITION-1:
news.abbvie.com/news/abbvies-investigati...nsated-cirrhosis.htm